HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ICMAD Clutches To House Cosmetics Bill Before Specter Of ‘Activist FDA’

This article was originally published in The Rose Sheet

Executive Summary

Locke Lord attorney Sharon Blinkoff, general counsel for the small-business trade group, says the newly introduced Safe Cosmetics Modernization Act is crafted to update cosmetics regulations without making room for oppressive oversight or a revival of the aggressively conservative FDA of decades past.

You may also be interested in...



ICMAD Responds To Senate Proposal: Cosmetics Should Not Be Regulated Like Foods

Small business advocate says the Senate Health Committee’s discussion draft – the Modernization of Cosmetics Regulation Act – would impose burdens on industry on par with requirements for foods. But while food products continue to pose significant risks, “no such record exists for the cosmetics industry,” the trade group asserts.

ICMAD Beefs Up Lobbying To Deter 'Wrong Decision' In Congress

Pam Busiek, head of the Independent Cosmetic Manufacturers and Distributors, discusses the trade group's ongoing work in Washington where multiple, differently sized bills for updating cosmetics regulations are under consideration. Notably, ICMAD's roster of advocates now includes former FDA Cosmetics Director John Bailey.

Think FDA Inspections Are Painful Now? These Could Be The Good Old Days

ICMAD's recent regulatory workshop offered perspective from FDA's Linda Katz and industry experts on the inspection process for cosmetics facilities under current law. It's clear that FDA inspections can be an ordeal, but that would pale in comparison to challenges that could arise under the proposed Personal Care Products Safety Act.

Related Content

Topics

UsernamePublicRestriction

Register

RS109032

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel